144 results
S-3
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
to satisfy reporting requirements and obtain regulatory approvals in certain circumstances. You are solely responsible for complying with such reporting … shares, such Holder will be responsible for transferring good and valid title to the depositary. As such, a Holder will be deemed to represent
S-3
EX-5.1
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
not been responsible for investigating or verifying the accuracy of the facts, including statements of foreign law, or the reasonableness of any
10-Q
2024 Q1
EX-31.2
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
of the registrant as of, and for, the periods presented in this report;
The registrant’s other certifying officer(s) and I are responsible for establishing
10-Q
2024 Q1
EX-31.1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
of the registrant as of, and for, the periods presented in this report;
The registrant’s other certifying officer(s) and I are responsible
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
15 May 24
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:06pm
and commercialization of leflutrozole, a non-steroidal aromatase inhibitor. Under the terms of the agreement, ReproNovo, a reproductive medicine company, is responsible
DEF 14A
y4io72gaz971op7
24 Apr 24
Definitive proxy
7:30am
10-K
EX-4.2
l0ni x6jzqotro
27 Mar 24
Annual report
5:20pm
10-K
EX-31.1
m1tdfsi2 a9t
27 Mar 24
Annual report
5:20pm
10-K
z5woxf2fax
27 Mar 24
Annual report
5:20pm
10-K
EX-10.30
ko3p2uwr 9n9x
27 Mar 24
Annual report
5:20pm
10-K
EX-31.2
445ayi86hlkgcide2c
27 Mar 24
Annual report
5:20pm
10-K
EX-19.1
cxp8 5qbttrb87k9v5
27 Mar 24
Annual report
5:20pm
8-K
EX-99.1
64g6ngwqcw82 vi
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
S-8
EX-5.1
v8l936w16mqykzb2d
23 Jan 24
Registration of securities for employees
4:16pm
8-K
EX-99.1
tkxgdy8
8 Jan 24
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
7:08am
6-K
EX-3.1
qlul5le5 pctnp
18 Dec 23
Current report (foreign)
4:10pm
6-K
EX-99.2
4tvi7hg9u2ei31tylmee
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.2
p3eb7b7hoor3eq5 1l
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
EX-99.2
4gm 5uxcd63u
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
yqhv1bvb1q 8u1
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am